Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?

Giulia Calabrese; Gaetano Licata; Alessio Gambardella; Alina De Rosa; Roberto Alfano; Giuseppe Argenziano

doi:10.5826/dpc.1201a155

Topical and Conventional Systemic Treatments in Atopic Dermatitis: Have They Gone Out of Fashion?

Authors

Giulia Calabrese Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Gaetano Licata Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Alessio Gambardella Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Alina De Rosa Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy
Roberto Alfano Department of Anesthesiology Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy
Giuseppe Argenziano Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

Keywords:

atopic dermatitis, treatments, therapy, topicals, systemic therapy

Abstract

Atopic dermatitis is a Th2 disease, due to relapse of IL-4 and IL-13 by Th2 cells. Despite the approval by FDA of dupilumab, the first monoclonal antibody for the severe forms, traditional drugs remain a milestone for the treatment of this dermatosis. Dermatologists need a good knowledge of all therapies for an integrated and personalized management of patients.

References

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287‐2303. DOI: 10.1016/S0140-6736(17)31191-1. PMID: 28478972.

Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328-1336. DOI: 10.1016/j.jaad.2020.02.060. PMID: 32135208.

Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39–45. DOI: 10.1016/j.jaad.2020.03.049. PMID: 32229281.

Ribero S, Giura MT, Viola R, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience. J Eur Acad Dermatol Venereol. 2020;34(8):e380-e383. DOI: 10.1111/jdv.16219. PMID: 31960496.

.Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32. DOI: 10.1016/j.jaad.2014.03.023. PMID: 24813302. PMCID: PMC4326095.

Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatol Ther. 2004;17 Suppl 1:49-56. DOI: 10.1111/j.1396-0296.2004.04s1006.x. PMID: 14728699.

Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009;8(1):40-43. DOI: 10.1111/j.1473-2165.2009.00422.x. PMID: 19250165.

Dabade TS, Davis DM, Wetter DA, et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100-6. DOI: 10.1016/j.jaad.2011.06.025. PMID: 21978575.

Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006;154(4):579-585. DOI: 10.1111/j.1365-2133.2006.07157.x. PMID: 16536797.

Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. DOI: 10.1016/j.jaad.2014.03.030. PMID: 24813298. PMCID: PMC4410179.

Nolan K, Marmur E. Moisturizers: reality and the skin benefits. Dermatol Ther. 2012;25(3):229-233. DOI: 10.1111/j.1529-8019.2012.01504.x. PMID: 22913439.

Furuhashi T, Oda T, Torii K, Nishida E, Morita A. Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis. J Dermatol. 2021;48(2):e74-e75. DOI: 10.1111/1346-8138.15638. PMID: 33035368; PMCID: PMC7891664.

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287‐2303. DOI: 10.1016/S0140-6736(17)31191-1. PMID: 28478972.

Treister AD, Kraff-Cooper C, Lio PA. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatol. 2018;154(10):1208‐1211. DOI: 10.1001/jamadermatol.2018.2690. PMID: 30167653. PMCID: PMC6233741.

Calabrese G, Gambardella A, Licata G, Di Brizzi EV, Alfano R, Argenziano G. Dupilumab and conjunctivitis: a case series of twenty patients. J Eur Acad Dermatol Venereol. 2021;35(9):e612-e614. DOI: 10.1111/jdv.17210. PMID: 33657247.

Jaros J, Hendricks AJ, Shi VY, Lio PA. A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis. Dermatitis. 2020;31(3):169-177. DOI: 10.1097/DER.0000000000000590. PMID: 32355092.

Gori N, Chiricozzi A, Malvaso D, et al. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. Dermatology. 2021;237(4):535-541. DOI: 10.1159/000512890. PMID: 33477153.

Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006; 367:839–846. DOI: 10.1016/S0140-6736(06)68340-2. PMID: 16530578.